Botanix Pharmaceuticals (ASX:BOT) is a clinical stage dermatology company developing novel treatments for common skin diseases and infection leveraging its novel delivery technology, Permetrex™. We have attracted a world-class team and significant capital to support the progression of our products. We are moving quickly, but never at the expense of our rigorous commitment to ethical research and development (R&D) and the highest clinical standards mandated by the US Food and Drug Administration (FDA). Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach.